search
Back to results

Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study

Primary Purpose

Retained Placenta

Status
Completed
Phase
Phase 4
Locations
Thailand
Study Type
Interventional
Intervention
nitroglycerine
NSS
Sponsored by
Mahidol University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Retained Placenta focused on measuring retained placenta

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy pregnant patient (ASA classification I ,II )
  • Normal pregnancy with at least 28 week gestation

Exclusion Criteria:

  • ASA classification III and up
  • Having complication of pregnancy such as hypertensive disease of pregnancy,

Sites / Locations

  • Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

1

2

Arm Description

1=nitroglycerine 100 microgram intravenous100-200 microgram of IV.

2=placebo with the same volume as NTG 100-200 microgram of IV.

Outcomes

Primary Outcome Measures

successful of placenta extraction

Secondary Outcome Measures

hypotension
headache
blood loss

Full Information

First Posted
June 28, 2008
Last Updated
March 6, 2011
Sponsor
Mahidol University
search

1. Study Identification

Unique Protocol Identification Number
NCT00707928
Brief Title
Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study
Official Title
Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2008
Overall Recruitment Status
Completed
Study Start Date
February 2008 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Mahidol University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary objective The primary objective of this study is to see whether intravenous (IV) NTG 100-200 microgram can effectively help extract retained placenta as compared to placebo, in a randomized controlled multicenter study. Secondary objective is to compare the hypotensive effects of NTG as compared to placebo, including others side effects such as headache, blood loss, or others.
Detailed Description
After the approval of the Ethical committee of each institute, and consent signed by the patient, 100 patients with retained placenta were divided into 2 groups in 5 tertiary care centers, university hospitals. By using the program research randomizer (from www. Randomizer.org/form.htm), with the block of 10 and the numbers within the concealed envelopes, totally 100 patients with retained placenta will be divided into 2 groups to have either 100-200 microgram of IV, NTG or IV placebo. Due to unequal number of the cases enrolled in each centers, they will receive 10 envelopes for 10 cases (5 NTG and 5 placebo) at a time. When they finish the first 10 cases, they will start another 10 cases of the next set until all 10 sets has been started. Each of 5 centers might enroll the cases between 10 to 40 cases up to their populations.. Once a diagnosis of retained placenta has been made ( ≥ 30 min after delivery), Hematocrit will be checked and IV crystalloid solution 500 ml has been rapidly perfuse and noninvasive monitored included pulse oximetry, electrocardiogram and noninvasive blood pressure will be monitored. Patients with signs of hypovolemia ( SBP < 100 mmHg, or pulse > 100/min), or ASA classification > II will be excluded from the study. First step: In the treatment group, 100 microgram of NTG will be given and wait for 80 seconds ( maximum relaxation effects of IV NTG)(5,6) before starting gently cord traction (1min). If the placenta can not be extracted, another 100 microgram NTG from the same syringe will be given and wait for another 80 seconds before starting another extraction (1min), If the placenta can not be extracted, it will be considered failed. In the placebo group, NSS will be used instead of NTG. Second step: To give a chance for patients in placebo group, another syringe with 200 microgram will be given as in the first step for the placebo group. In the treatment group, NSS will be used instead of NTG. The outcome in the second step will not be included in the first step.( The solutions in both syringes which will be prepared by the research assistant who will not involve in the study, will be blinded to the patient, the obstetrician, the anesthesiologist and the investigator) General anesthesia will be used for manual removal of placenta in cases that placenta can not be extracted after the second step. Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful. Vital signs will be recorded before the first NTG bolus and thereafter at 1 min interval for 5 min then every 2 min for 10 min then every 5 min. for 20 min(see the CRF). The patient will be followed up closely for 24 h postoperatively and Hct will be checked , including the final results upon discharge home.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Retained Placenta
Keywords
retained placenta

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
1=nitroglycerine 100 microgram intravenous100-200 microgram of IV.
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
2=placebo with the same volume as NTG 100-200 microgram of IV.
Intervention Type
Drug
Intervention Name(s)
nitroglycerine
Other Intervention Name(s)
trinitroglycerin,trinitroglycerine,glyceryl trinitrate
Intervention Description
nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
Intervention Type
Other
Intervention Name(s)
NSS
Other Intervention Name(s)
normal saline
Intervention Description
NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
Primary Outcome Measure Information:
Title
successful of placenta extraction
Time Frame
5 mintues
Secondary Outcome Measure Information:
Title
hypotension
Time Frame
20 mintues
Title
headache
Time Frame
2 hour
Title
blood loss
Time Frame
24 hour

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy pregnant patient (ASA classification I ,II ) Normal pregnancy with at least 28 week gestation Exclusion Criteria: ASA classification III and up Having complication of pregnancy such as hypertensive disease of pregnancy,
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shusee Visalyaputra, MD
Organizational Affiliation
Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand

12. IPD Sharing Statement

Learn more about this trial

Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study

We'll reach out to this number within 24 hrs